1. Home
  2. INNV vs ENTA Comparison

INNV vs ENTA Comparison

Compare INNV & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InnovAge Holding Corp.

INNV

InnovAge Holding Corp.

HOLD

Current Price

$4.99

Market Cap

485.4M

Sector

Health Care

ML Signal

HOLD

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$14.51

Market Cap

407.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INNV
ENTA
Founded
2007
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
485.4M
407.5M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
INNV
ENTA
Price
$4.99
$14.51
Analyst Decision
Sell
Strong Buy
Analyst Count
2
5
Target Price
$5.00
$20.40
AVG Volume (30 Days)
242.5K
288.8K
Earning Date
11-04-2025
11-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$884,662,000.00
$65,324,000.00
Revenue This Year
$11.18
$0.99
Revenue Next Year
$9.58
$0.19
P/E Ratio
N/A
N/A
Revenue Growth
12.48
N/A
52 Week Low
$2.60
$4.09
52 Week High
$6.26
$15.34

Technical Indicators

Market Signals
Indicator
INNV
ENTA
Relative Strength Index (RSI) 48.23 72.93
Support Level $4.94 $11.89
Resistance Level $5.21 $14.52
Average True Range (ATR) 0.44 0.86
MACD -0.02 0.10
Stochastic Oscillator 17.42 95.27

Price Performance

Historical Comparison
INNV
ENTA

About INNV InnovAge Holding Corp.

InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Share on Social Networks: